ABN AMRO Bank N.V. Purchases New Shares in United Therapeutics Corporation $UTHR

ABN AMRO Bank N.V. purchased a new position in United Therapeutics Corporation (NASDAQ:UTHR) during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 7,444 shares of the biotechnology company’s stock, valued at approximately $4,422,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of the stock. Torren Management LLC purchased a new stake in United Therapeutics during the fourth quarter valued at about $26,000. Activest Wealth Management increased its position in shares of United Therapeutics by 1,400.0% in the fourth quarter. Activest Wealth Management now owns 60 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 56 shares in the last quarter. WealthCollab LLC increased its position in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 38 shares in the last quarter. Rakuten Securities Inc. raised its holdings in shares of United Therapeutics by 76.7% during the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Finally, Entrust Financial LLC acquired a new stake in shares of United Therapeutics during the fourth quarter valued at approximately $31,000. Institutional investors and hedge funds own 94.08% of the company’s stock.

United Therapeutics Price Performance

NASDAQ UTHR opened at $542.66 on Friday. The firm has a market capitalization of $23.04 billion, a price-to-earnings ratio of 20.03, a price-to-earnings-growth ratio of 1.79 and a beta of 0.57. The company has a 50 day simple moving average of $561.23 and a 200-day simple moving average of $525.58. United Therapeutics Corporation has a 52-week low of $272.12 and a 52-week high of $609.35.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 EPS for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to analysts’ expectations of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The business’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the previous year, the firm posted $6.63 earnings per share. On average, analysts predict that United Therapeutics Corporation will post 26.49 EPS for the current year.

Insider Buying and Selling at United Therapeutics

In other news, EVP Paul A. Mahon sold 8,300 shares of the business’s stock in a transaction on Thursday, June 18th. The shares were sold at an average price of $541.55, for a total transaction of $4,494,865.00. Following the transaction, the executive vice president directly owned 45,172 shares in the company, valued at $24,462,896.60. The trade was a 15.52% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Martine A. Rothblatt sold 9,500 shares of the company’s stock in a transaction on Wednesday, June 24th. The stock was sold at an average price of $548.69, for a total transaction of $5,212,555.00. Following the completion of the transaction, the chief executive officer directly owned 40,513 shares in the company, valued at $22,229,077.97. This trade represents a 19.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold 643,218 shares of company stock valued at $363,705,304 in the last quarter. Company insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on UTHR. Royal Bank Of Canada decreased their price objective on shares of United Therapeutics from $707.00 to $701.00 and set an “outperform” rating for the company in a research note on Thursday, May 7th. Morgan Stanley set a $516.00 target price on shares of United Therapeutics in a research note on Thursday, May 7th. Cantor Fitzgerald increased their target price on United Therapeutics from $525.00 to $625.00 and gave the company an “overweight” rating in a report on Thursday, March 12th. UBS Group raised their target price on United Therapeutics from $655.00 to $705.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of United Therapeutics in a report on Monday, March 2nd. Eleven research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $619.42.

About United Therapeutics

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.